AB040. Determinants of increase FeNO in individuals with suspected asthma

• DOI: 10.21037/jtd.2016.s040
• Publication Date: 2016-07-20T06:10:20Z
• Authors: Maria Batsiou; Sandra Kreuzaler; Elizabeth Gardener; Dermot Ryan; Kevin Gruffydd-Jones; Mike Thomas; Roland Buhl; Jörgen Syk; Anne Copland; Daryl Freeman; Therese S. Lapperre; Clifford Godley; Ken Ohta; Tze L. Tan; Tan Ngiap Chuan; Vicky Thomas; Priyanka Raju; Mark Harris; Andrew McLoughlin; David Price
• Keywords: 2. Zero hunger; 03 medical and health sciences; 0302 clinical medicine; 3. Good health

Background Airway inflammation is the fundamental mechanism in asthma and can be measured non-invasively by means of fractional exhaled nitric oxide (FeNO). Both, The National Institute for Health and Care Excellence (NICE) diagnostics guidance 12 and British guideline on the management of asthma, are recommending the inclusion of FeNO testing as part of diagnosis in patients that have an intermediate probability of having asthma. Furthermore, FeNO testing is recommended as an option for monitoring response to corticosteroid treatment in patients with increased FeNO. However, there is a need for establishing routine data predictors for individuals with increased FeNO, to identify those that would benefit from FeNO measurement as a tool for aiding asthma diagnosis and monitoring treatment responsiveness. To provide a real-life predictive model for the identification of individuals at risk of asthma that have increased FeNO.